title: Combination Interferon alfa-2b/ribavirin therapy for the treatment of hepatitis C: nursing implications.
abstract: An effective new therapeutic option consisting of Intron A (Interferon alfa-2b, recombinant; Schering Corporation, Kenilworth, NJ) Injection and Rebetol (Ribavirin, USP) Capsules is now available for the initial therapy of patients with hepatitis C and for patients who had previously responded to alpha interferon but subsequently relapsed. The combination of recombinant interferon alfa-2b/ribavirin therapy increases hepatitis C viral clearance 10-fold in hepatitis C relapse patients and almost threefold in previously untreated patients compared with alpha interferon monotherapy. There is no synergistic toxicity apparent with the two-drug combination. Ribavirin does not significantly worsen the side effects associated with interferon alfa-2b, which are predictable, manageable, and reversible. The major side effects of combination therapy include flulike symptoms, neutropenia, psychiatric disorders, and anemia; however, these side effects are well known and can be managed with dose modifications and nursing intervention. The assistance of nurses in patient education, in side effect management, in hematologic parameter monitoring, and in medication dosing and administration is crucial to maximizing patient compliance and therapy outcome.
authors: Schering Oncology/Biotech, Kenilworth, NJ 07033, USA.
authors: A
authors: A
authors: Birkel
authors: L
authors: L
authors: Caldwell
authors: V
authors: V
authors: Stafford-Fox
authors: B
authors: B
authors: Casarico
authors: L
authors: L
authors: Benson
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000451:nursing* / Q000523:psychology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D010349:Patient Compliance; D010353:Patient Education as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin